Chakradhar Reddy, MD
Gastroenterology · Johnson City, TNNPI 1548360332
Payments from drug & device makers
Across 932 payments — averaging $948.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$291K
- Intercept Pharmaceuticals, Inc.$198K
- Janssen Research & Development, LLC$137K
- Gilead$137K
- Madrigal Pharmaceuticals$39K
- Novo Nordisk AS$33K
- plus $49K from 26 others
Across 92 payments — averaging $3975.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$342K
- Intercept Pharma Europe Ltd.$17K
- Regeneron$7K
What the payments were for
- Consulting fees$5,0783%
- Speaking & faculty fees$132,04482%
- Travel & lodging$16,58010%
- Food & beverage$6,4634%
- Education$3870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 253 | $290,544 |
| Intercept Pharmaceuticals, Inc. | 63 | $197,792 |
| Janssen Research & Development, LLC | 54 | $137,496 |
| Gilead | 138 | $137,413 |
| Madrigal Pharmaceuticals | 17 | $38,904 |
| Novo Nordisk AS | 265 | $33,217 |
| Genentech, Inc. | 4 | $21,000 |
| Bausch Health US, LLC | 1 | $9,100 |
| Ipsen Biopharmaceuticals, Inc | 6 | $8,469 |
| F. Hoffmann-la Roche AG | 1 | $5,000 |
| Dova Pharmaceuticals | 3 | $3,076 |
| Novo Nordisk | 12 | $387 |
| Johnson & Johnson | 24 | $353 |
| Bristol Myers Squibb | 20 | $274 |
| Pfizer | 24 | $270 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $231 |
| Boston Scientific | 3 | $133 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $118 |
| Daiichi Sankyo Inc. | 5 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $66 |
| Romark Laboratories, LC | 3 | $45 |
| Lilly USA, LLC | 2 | $35 |
| Enterra Medical, Inc. | 1 | $33 |
| Mauna Kea Technologies, Inc. | 2 | $30 |
| Ferring Pharmaceuticals Inc. | 2 | $27 |
| Conmed Corporation | 1 | $22 |
| Sanofi | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Braintree Laboratories, Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Evoke Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$884,317 in reported general payments places this provider in the 95th percentile of 336 gastroenterology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 29 | $96,490 |
| MotegrityPrucalopride Succinate | 12 | $7,063 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 96 | $5,755 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 27 | $4,072 |
| Colestipol Hcl | 39 | $2,038 |
| Omeprazole | 130 | $2,007 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 129 | $1,986 |
| Ursodiol | 12 | $1,305 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 65 | $915 |
| Ondansetron OdtOndansetron | 18 | $850 |
| Sucralfate | 30 | $797 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 45 | $697 |
| Pantoprazole Sodium | 54 | $657 |
| Ondansetron Hcl | 19 | $346 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 12 | $291 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $231 | $96,49029 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $66 | $7,06312 claims |
| Braintree Laboratories, Inc.Sutab | $16 | $4,07227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 336 gastroenterology providers in Tennessee.
Other gastroenterology in Johnson City
- Ziad YounesGermantown$15.6M
- Robert HerringNashville$3.2M
- Dawn Borromeo BeaulieuNashville$2.1M
- David SchwartzNashville$1.4M
- Kevin FinneganHermitage$1.4M
- Baldeep PablaNashville$1.2M
- Sara HorstNashville$1.2M
- Michael PoraykoNashville$870K
- Saras SharmaNashville$870K
- Robin DalalNashville$847K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.